July 15 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* Q2 net sales 34.5 million Swedish crowns ($4.1 million) versus 29.1 million crowns year
ago
* Q2 EBITDA ex-items 6.9 million crowns versus 4.6 million crowns year ago
* Says focus during 2016 is therefore to establish STEEN Solution method as the standard
treatment for lung transplantation
* Since acquisition of Vivoline company will intensify research and development in cardiac
transplantation
Source text for Eikon: ID:nWkrgn7235
Further company coverage: XVIVO.ST
($1 = 8.4907 Swedish crowns)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))